However, expanding this search to include all types of cancers, across 69223 patient samples, the database indicated ARRDC3 mutation (loss/amplification) co-occurred significantly (two-sided Fischer exact tests, each p < 0.001) with both MYC amplificiation and TP53 loss. This evidence concerns the gene ARRDC3 and cancer.